No Protective Effect of the NMDA Antagonist Memantine in Experimental Spinal Cord Injuries
- 1 January 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Neurotrauma
- Vol. 14 (1) , 53-61
- https://doi.org/10.1089/neu.1997.14.53
Abstract
We have investigated the effect of memantine, a clinically used NMDA receptor antagonist, in two experimental animal models of spinal cord injury. The lesions were laser-induced photothrombosis to induce focal spinal cord ischemia and clip compression to mimic traumatic spinal cord injury. Pre- or posttreatment of rats with a dose of memantine (20 mg/kg ip) previously shown to be neuroprotective in cerebral ischemia, failed to affect both the neurological and morphological outcome of ischemic spinal cord injury. Likewise, memantine had no effects on neurological and morphological outcome after experimental traumatic injury. In view of the regional heterogeneity of NMDA receptors, the affinity of memantine for spinal cord NMDA receptors was also determined by studying displacement of [3H](+)-5-methyI-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-10-imine (MK-801) to rat and human spinal cord homogenates. We found that memantine had an affinity for NMDA receptors in the spinal cord (Ki = 0.58 μM) that was significantly lower compared to that of the cerebral cortex (Ki = 0.23 μM) and that the affinity for NMDA receptors in human spinal cord was even lower. We conclude that in view of available data, memantine should not be chosen for clinical studies on neuroprotection in spinal cord injuries and that the lack of protective effect is most likely due to insufficient affinity of memantine for spinal cord NMDA receptors. Key words: memantine, neuroprotection, N-methyl-d-aspartate receptor, spinal cord injuryKeywords
This publication has 27 references indexed in Scilit:
- Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f] quinoxaline.Proceedings of the National Academy of Sciences, 1996
- Different binding affinities of NMDA receptor channel blockers in various brain regions—Indication of NMDA receptor heterogeneityNeuropharmacology, 1995
- Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicityJournal of Neuroscience, 1992
- Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodentsEuropean Journal of Pharmacology, 1992
- Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartateEuropean Journal of Pharmacology, 1991
- Effects of competetive and non-competetive NMDA receptor antagonists in spinal cord injuryEuropean Journal of Pharmacology, 1990
- Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemiaJournal of Neuroscience, 1990
- Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channelsEuropean Journal of Pharmacology, 1989
- A potential role for excitotoxins in the pathophysiology of spinal cord injuryAnnals of Neurology, 1988
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973